Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
85
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience

Melis Gönülal1 Department of Dermatology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, İzmir, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6042-656XView further author information
ORCID Icon,
Didem Didar Balcı1 Department of Dermatology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, İzmir, TurkeyView further author information
&
Serap Öztürkcan2 Department of Dermatology, Manisa Celal Bayar University Hafsa Sultan Hospital, Manisa, TurkeyView further author information
Pages 3653-3659 | Received 19 Oct 2023, Accepted 13 Dec 2023, Published online: 19 Dec 2023

References

  • Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017;376(16):1551–1560. doi:10.1056/NEJMoa1607017
  • Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther. 2018;12:3879–3883. doi:10.2147/DDDT.S167149
  • Cline A, Feldman SR. Risankizumab for psoriasis. Lancet. 2018;392(10148):616–617. doi:10.1016/S0140-6736(18)31781-1
  • Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: a Review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
  • Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: a Review of the Real-World Evidence. Clin Cosmet Invest Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
  • Tokuyama M, Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci. 2020;21(20):7488. doi:10.3390/ijms21207488
  • Gu C, Yang J. Risankizumab for the treatment of psoriasis. Expert Rev Clin Pharmacol. 2019;12(9):851–857. doi:10.1080/17512433.2019.1657829
  • Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
  • Augustin M, Lambert J, Zema C, et al. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: the UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020;156(12):1344–1353. doi:10.1001/jamadermatol.2020.3617
  • Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a Phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–59. doi:10.1111/bjd.19341
  • Crowley JJ, Langley RG, Gordon KB, et al. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: subgroup Analysis from the IMMerge Study. Dermatol Ther (Heidelb). 2022;12(2):561–575. doi:10.1007/s13555-021-00679-6
  • Gkalpakiotis S, Cetkovska P, Arenberger P. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: real-Life Multicenter Experience from the Czech Republic. Dermatol Ther (Heidelb). 2021;11(4):1345–1355. doi:10.1007/s13555-021-00556-2
  • Borroni RG, Malagoli P, Gargiulo L, et al. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: a 40-week Multicentric Retrospective Study. Acta Derm Venereol. 2021;101(11):adv00605. doi:10.2340/actadv.v101.283
  • Caldarola G, Zangrilli A, Bernardini N, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6):e15489. doi:10.1111/dth.15489
  • Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J DermatolTreat. 2023;34(1):2133531. doi:10.1080/09546634.2022.2133531
  • Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients With moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658. doi:10.1001/jamadermatol.2020.0723
  • Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with Adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. doi:10.1016/S0140-6736(19)30952-3
  • Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
  • Hansel K, Zangrilli A, Bianchi L, et al. A multicenter study on effec- tiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021;35(3):e169–e170. doi:10.1111/jdv.17003
  • Gargiulo L, Ibba L, Pavia G, et al. Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309–2324. doi:10.1007/s13555-022-00795-x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.